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Exposure to lead is known to affect the cardio-
vascular system, even at low, general environ-
mental levels. Many epidemiologic studies
have shown an association between chronic
low-level lead exposure and hypertension (Hu
et al. 1996; Korrick et al. 1999; Nash et al.
2003) and cardiovascular disease (Cheng et al.
1998; Lustberg and Silbergeld 2002; Schwartz
1991). One possible mechanism for this asso-
ciation is interference in autonomic nerve con-
trol of the heart. Experimental studies have
shown that lead can generate reactive oxygen
species (ROS) by depletion of glutathione and
protein-bound sulfhydryl groups, leading to
oxidative stress (Gurer and Ercal 2000).
Oxidative stress plays an important role in the
production of proinflammatory mediators,
lipid peroxidation, the suppression of nitric
oxide, and alteration of calcium homeostasis,
which may increase central sympathetic nerve
activity and reduce baroreflex sensitivity and
vagal parasympathetic tone (Ding et al. 2000;
Dursun et al. 2005; Vaziri 2002). 
Heart rate variability (HRV) is a non-
invasive and quantitative marker of cardiac
autonomic function that reflects the regulation
of the sinoatrial node by the sympathetic and
parasympathetic branches of the autonomic
nervous system [Task Force of the European
Society of Cardiology and the North American
Society of Pacing and Electrophysiology (Task
Force) 1996]. Decreased HRV is an indepen-
dent predictor of mortality in middle-aged
and elderly subjects, in patients with diabetes,
and in survivors of myocardial infarction and
other coronary heart diseases (Gerritsen et al.
2001; Tapanainen et al. 2002; Tsuji et al.
1996). Several studies of workers occupation-
ally exposed to lead support the contention
that lead acts upon the heart via the auto-
nomic nervous system (Bockelmann et al.
2002; Murata and Araki 1991; Murata et al.
1993; Teruya et al. 1991). A recent study
from Korea on subjects nonoccupationally
exposed to lead showed significant univariate
associations between blood lead and HRV
measures, but failed to find the associations
after adjustment for confounding variables,
such as age, alcohol consumption, and other
blood metal concentrations (Jhun et al. 2005).
In a community-based study of the relation-
ship between bone lead and cardiac conduc-
tion among elderly men environmentally
exposed to lead, our group previously found
that higher bone lead levels were associated
with electrocardiographic (ECG) features such
as longer QT and QRS intervals and intra-
ventricular and atrioventricular conduction
defects, suggesting depressed cardiac conduc-
tion (Cheng et al. 1998). This could be evi-
dence that even low-level exposure to lead
may alter autonomic activity, because cardiac
conduction is mediated, in part, through a
branch of the autonomic nervous system
(Ahnve and Vallin 1982). 
Another issue in the study of lead toxicity
is the identification of susceptible population
groups, such as those with preexisting cardio-
vascular conditions. For example, people with
metabolic syndrome (MetS), a cluster of
health risks including obesity, diabetes, hyper-
tension, and dyslipidemia (Moller and
Kaufman 2005), are at greater risk of cardio-
vascular disease because they are likely to have
stronger levels of oxidative-stress–induced
inflammatory responses. As a result, they may
be less able to homeostatically control
responses to additional oxidative stressors such
as lead exposure and therefore show more pro-
nounced responses. Recently, Tsaih et al.
(2004) observed that lead had a more pro-
nounced effect on renal function in people
with diabetes and hypertension. However, to
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BACKGROUND: Altered heart rate variability (HRV), a marker of poor cardiac autonomic function,
has been associated with sudden cardiac death and heart failure.
OBJECTIVE: We examined the association of low-level lead exposure measured in bone by K-X-ray
fluorescence with alterations in HRV, and whether metabolic syndrome (MetS) or its individual
components modify those associations.
METHODS: HRV measures [power in high-frequency (HFnorm) and low-frequency (LFnorm) in nor-
malized units, and LF/HF] were taken among 413 elderly men from the Normative Aging Study.
MetS was defined as subjects having three or more of the following criteria: abdominal obesity,
hypertriglyceridemia, low high-density lipoprotein, high blood pressure, and high fasting glucose.
RESULTS: Of the subjects, 32% were identified as having MetS. Inverse but nonstatistically signifi-
cant associations of both tibia and patella lead levels with HFnorm and nonstatistically significant
positive relations with LFnorm and LF/HF were found in the entire cohort. There was a graded, sta-
tistically significant reduction in HFnorm and increases in LFnorm and LF/HF in association with an
increase in patella lead as the number of metabolic abnormalities increased. We also observed that
higher patella lead was consistently associated with lower HFnorm and higher LFnorm and LF/HF
among subjects with MetS or its individual components. No statistically significant interaction
between MetS and tibia lead was observed.
CONCLUSION: The results suggest that elderly men with MetS were more susceptible to autonomic
dysfunction in association with chronic lead exposure as measured in patella. The modification by
MetS is consistent with a role for oxidative stress in lead toxicity on the cardiovascular system.
KEY WORDS: autonomic nervous system, bone lead, heart rate variability, hypertension, metabolic
syndrome. Environ Health Perspect 114:1718–1724 (2006). doi:10.1289/ehp.8992 available via
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our knowledge, no previous study has exam-
ined modifications of the association between
lead exposure and HRV by clinical conditions,
such as MetS, diabetes, and hypertension. 
In this study we examined the association
of low-level lead exposure (measured in bone)
with alterations in HRV among community
residents with no previously known heavy lead
exposure. We also assessed effect modifications
by MetS and its individual components.
Materials and Methods
Study population. The Normative Aging
Study is a longitudinal study established by
the Veterans Administration (VA; now the
U.S. Department of Veterans Affairs) in 1963,
when 2,280 community-dwelling men from
the Greater Boston area 21–80 years of age
were enrolled (Bell et al. 1972). All partici-
pants were free of known chronic medical
conditions at enrollment. Every 3–5 years,
participants underwent physical examination
such as assessment of body mass index (BMI)
and measurement of systolic and diastolic
blood pressures. During these visits, partici-
pants filled out questionnaires on cigarette
smoking, food frequency, and various health
risk factors. In addition, data on fasting blood
glucose, total cholesterol, and high-density
lipoprotein (HDL) cholesterol were also
obtained from blood samples. Participants vis-
ited the study center in the morning after an
overnight fast and abstinence from smoking.
From 1991 to 2002, Normative Aging
Study participants who gave their informed
consent were invited to undergo bone lead
measurements. If subjects had more than one
bone lead measurement during this period
(75% of subjects analyzed; mean = 1.7, maxi-
mum = 4), the measurement closest to the date
of the HRV measurement was used for this
analysis. In 98 subjects (23.7%), the bone lead
levels were measured after the HRV measures
were obtained. However, all of those bone lead
measurements were obtained within 6 months
of the HRV measurement. Because half-lives of
tibia lead and patella lead are years to decades,
we do not think that bone lead levels at the
time of HRV measurement would have been
different from those actually measured. In an
earlier analysis, no important differences were
detected between Normative Aging Study par-
ticipants who did and did not have bone lead
measurements taken (Cheng et al. 1998). 
Beginning in November 2000, HRV meas-
urement was added to the tests performed dur-
ing the regular visits of Normative Aging Study
subjects. Among active cohort members,
671 persons were examined for HRV from
14 November 2000 to 22 December 2004.
Excluded were 110 subjects (16.4%) with
problematic heart rate measurements, includ-
ing atrial fibrillation, atrial bigeminy or
trigeminy, pacemakers, irregular rhythm,
irregular sinus rhythm, frequent ventricular
ectopic activity, ventricular bigeminy, multi-
focal atrial tachycardia, or measurement time
< 3.5 min. We further excluded 131 and
142 subjects without tibia or patella lead
measurements, respectively; 10 subjects with
high bone lead measurement uncertainties
(≥ 10 µg/g and 15 µg/g for tibia and patella,
respectively); 5 and 9 subjects with extreme
tibia and patella lead levels, respectively; and
2 subjects with missing values of the potential
confounding factors. Hence, 413 (tibia) and
398 (patella) subjects were available for lead
analyses. All participants had given written
informed consent. This study was reviewed
and approved by the institutional review
boards of all participating institutions. 
HRV measurement. HRV was measured
between 0600 and 1300 hours using a two-
channel (five-lead) ECG monitor (Trillium
3000; Forest Medical, East Syracuse, NY).
After the participants had rested for 5 min,
the ECG was recorded (sampling rate of
256 Hz/channel) for approximately 7 min
with the subject seated. We used the best
4-consecutive-min interval for the HRV cal-
culations. The ECG digital recordings were
processed, and heart rate and HRV measures
were calculated using PC-based software
(Trillium 3000 PC Companion Software for
MS Windows; Forest Medical), which con-
forms to established guidelines (Task Force
1996). Beats were automatically detected and
assigned tentative annotations, which were
then reviewed by an experienced scanner to
correct for any mislabeled beats or artifacts. We
used only normal-to-normal (NN) beat inter-
vals in the analysis; SD of NN intervals
(SDNN) was calculated. We also computed
high frequency (HF; 0.15–0.4 Hz), low fre-
quency (LF; 0.04–0.15 Hz), and LF/HF ratio.
HF and LF were also included as normalized
units (HFnorm and LFnorm), which reflect the
relative value of each power component in pro-
portion to the total power minus the very low
frequency component. An example of time
domain R–R interval data and the estimate of
power spectral density is shown in Figure 1.
Spectral analysis of the time domain trans-
forms the signal from time to frequency on the
x-axis using a Fast Fourier transformation, by
representing the signal as a combination of sine
and cosine waves, with different amplitudes
and frequencies. Table 1 describes various
HRV parameters measured in this study. HF
represents an estimate of parasympathetic
(vagal) activity. The interpretation of LF is
more controversial. Some studies consider LF,
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Table 1. HRV measures used in this study.
HRV measures (units) Description
SDNN (msec) SD of all NN intervals, an estimate of overall variability
HF (msec2) High frequency power (0.15–0.4 Hz), a marker of parasympathetic (vagal) modulation
HFnorm (nu) HF power in normalized units, HF/(total power – very low frequency power) × 100
LF (ms2) Low frequency power (0.04–0.15 Hz), a marker of both sympathetic and vagal modulations
LFnorm (nu) LF power in normalized units, LF/(total power – very low frequency power) × 100, a marker 
of sympathetic modulation
LF/HF Ratio LF [ms2]/HF[ms2], sympathovagal balance OR the sympathetic modulation
Figure 1. An example of time domain R-R interval data and the estimate of power spectral density. ULF,
ultra-low frequency; VLF, very low frequency.
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when expressed in normalized units, to be a
marker of sympathetic modulations, and other
studies regard LF as reflecting both sympa-
thetic and vagal activity. Consequently, LF/HF
represents an estimate of sympathovagal bal-
ance or the sympathetic modulation (Task
Force 1996). For simplicity, we present only
the results for HFnorm, LFnorm, and LF/HF,
which explain associations with the sympa-
thetic and vagal modulations of the heart.
Room temperature where the HRV measure-
ment was taken was also recorded. 
Bone lead measurements. Bone lead levels
were measured at the midtibial shaft and the
patella using a K-shell X-ray fluorescence
(KXRF) instrument (ABIOMED, Danvers,
MA). The physical principles, technical specifi-
cations, and validation of this instrument have
been described in detail (Burger et al. 1990).
The tibia and patella were targeted for bone
lead research because they consist mainly of
pure cortical and pure trabecular bone, respec-
tively, and thus represent the two main bone
compartments. Lead in trabecular bone has a
faster turnover rate and therefore reflects more
recent exposure than that in cortical bone. The
KXRF instrument provides an unbiased esti-
mate of bone lead levels (normalized for bone
mineral content as micrograms of lead per
gram of bone mineral) and an estimate of the
uncertainty associated with each measurement. 
Most bone lead measurements were
obtained before the HRV measurement
(median, 3.2 years). Kim et al. (1997) reported
that an individual’s patella bone lead decreased
by 23% over a 3-year follow-up in this same
population (7.67% decrease/year), but tibia
lead levels did not change. To account for
the declining trend in patella lead levels, we
predicted estimated patella lead levels as 
Patella lead × (1 – 0.0767)d,
where d denotes the difference in years between
dates of bone lead and HRV measurement.
MetS and individual metabolic abnor-
malities. We used the criteria of the National
Cholesterol Education Program Adult
Treatment Panel III (Ford et al. 2002; Moller
and Kaufman 2005) and defined subjects
having three or more of the following criteria
as having MetS: a) abdominal obesity (waist
circumference > 102 cm in men); b) hyper-
triglyceridemia (≥ 150 mg/dL); c) low HDL
cholesterol (< 40 mg/dL in men); d) high
blood pressure (≥ 130/85 mm Hg); and
e) high fasting glucose (≥ 110 mg/dL). We
counted subjects who reported currently
using hypertension or diabetes medication as
having high blood pressure or high fasting
glucose, respectively. Subjects whose waist
circumference measurement was missing
(n = 13) were counted as having abdominal
obesity if their BMI was ≥ 30 kg/m2.
To investigate effect modifications by indi-
vidual components of the MetS, we used
stricter definitions. Diabetes was defined as fast-
ing blood glucose of ≥ 126 mg/dL, a physi-
cian’s diagnosis of type 2 diabetes, and/or use of
a diabetes medication (e.g., oral hypoglycemic
drug, metformin, or insulin). Hypertension was
defined as reported use of hypertension medica-
tion, systolic blood pressure of ≥ 160 mmHg,
or diastolic blood pressure of ≥ 96 mmHg.
Because the prevalence of high blood pressure
was relatively high in this population (67%),
these high cutoff points were chosen to main-
tain a high degree of specificity among those
subjects assigned as hypertensive (Hu et al.
1996). Abdominal obesity was defined as
waist circumference ≥ 106 cm (75th per-
centile). Dyslipidemia was defined as hyper-
triglyceridemia (triglyceride of ≥ 150 mg/dL)
and low HDL cholesterol levels (< 40 mg/dL). 
Statistical methods. Extreme outliers in
bone lead measures were identified and
removed using the generalized extreme stu-
dentized deviation many-outlier method
(Rosner 1983), as in previous analyses (Hu
et al. 1996). 
Linear regression analyses were conducted
to evaluate the relation of HRV with each
lead marker. LF/HF was log10-transformed to
improve normality and stabilize variance. The
potential confounding factors were age, BMI,
fasting blood glucose, HDL, triglyceride,
cigarette smoking (current/former/never),
alcohol consumption (two or more drinks a
day, yes/no), use of beta-blockers, use of cal-
cium channel blockers, use of angiotensin
converting enzyme (ACE) inhibitors, room
temperature, and season. We present effect
estimates for an increment of the interquartile
range (IQR) for each lead marker. For log-
transformed LF/HF, the percent change for
an increase of the IQR for each lead marker
was estimated as [10(β × IQR) – 1] × 100%,
with 95% confidence intervals (CIs)
{10[IQR × (β ± 1.96 × SE)] – 1} × 100%, where β is
the estimated regression coefficient. To assess
modifying effects of MetS and other meta-
bolic abnormalities, we ran regression models
including multiplicative interaction terms
along with the main effects. 
To evaluate the linear regression assump-
tion, penalized splines were used to allow the
Park et al.
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Table 2. Characteristics of study population according to the number of metabolic abnormalities. 
Study participants
No. of metabolic abnormalitiesa
All (n = 413) 0 (n = 60) 1–2 (n = 220) ≥ 3 (n = 133)
Bone lead [median (IQR)]
Tibia lead (µg/g) 19.0 (11.0–28.0) 18.5 (10.5–23.0) 19.0 (11.0–28.0) 19.0 (12.0–26.0)
Patella lead (µg/g)b 23.0 (15.0–34.0) 22.0 (13.5–32.0) 25.0 (16.0–36.0) 20.0 (15.0–32.0)
Estimated patella lead (µg/g)b,c 16.3 (10.4–25.8) 16.3 (10.8–24.8) 17.1 (11.0–29.3) 15.1 (9.4–22.1)
Continuous variables (mean ± SD)
Age (years) 72.9 ± 6.5 72.4 ± 7.7 73.5 ± 6.3 72.3 ± 6.0
Body mass index (kg/m2) 28.0 ± 4.0 25.0 ± 2.6 27.0 ± 3.0 30.9 ± 4.1*
Waist circumference (cm)d 99.7 ± 9.8 91.2 ± 6.6 97.5 ± 7.5 107.3 ± 9.3*
Systolic blood pressure (mmHg) 130.6 ± 16.8 125.3 ± 14.5 131.0 ± 17.1 132.3 ± 17.0*
Diastolic blood pressure (mmHg) 74.6 ± 10.1 73.5 ± 8.0 74.6 ± 10.2 75.0 ± 10.8
Heart rate (beats/min) 70.8 ± 6.9 70.9 ± 5.5 70.6 ± 6.7 71.0 ± 7.8
Fasting blood glucose (mg/dL) 107.6 ± 27.8 94.3 ± 7.3 101.1 ± 16.3 124.3 ± 39.0*
Cholesterol (mg/dL) 192.8 ± 37.0 205.9 ± 30.5 192.9 ± 36.6 186.7 ± 39.5*
High density lipoprotein (mg/dL) 49.3 ± 13.6 60.3 ± 16.0 51.2 ± 12.0 41.3 ± 9.8*
Triglyceride (mg/dL) 126.5 ± 67.6 86.5 ± 30.1 105.4 ± 47.2 179.4 ± 76.6*
Categorical variables (%)
Smoking status
Never-smoker 31.2 38.3 30.9 28.6
Former smoker 63.2 55.0 64.1 65.4
Current smoker 5.6 6.7 5.0 6.0
Alcohol intake (≥ 2 drinks/day) 19.4 18.3 22.7 14.3
Diabetes mellitus 20.6 0.0 10.9 45.9*
Ischemic heart disease history 29.1 13.3 29.6 35.3*
Stroke history 6.3 0.0 6.8 8.3*
Hypertension 70.9 11.7 76.8 88.0*
Use of β-blocker 34.6 0.0 36.4 47.4*
Use of Ca-channel blocker 14.0 0.0 14.1 20.3*
Use of ACE inhibitor 21.3 0.0 22.3 29.3*
Use of statin 37.1 20.0 35.0 48.1*
HRV [mean (median)]
SDNN (msec) 38.8 (34.0) 39.8 (35.5) 40.7 (35.0) 35.2 (30.0)
HF (msec2) 290.1 (71.0) 268.0 (79.0) 346.1 (67.5) 207.4 (71.0)
LF (msec2) 193.5 (96.0) 194.0 (117.5) 213.8 (100.0) 159.7 (83.0)
HFnorm (nu) 45.8 (41.8) 44.0 (40.1) 45.0 (39.7) 48.0 (47.4)
LFnorm (nu) 54.2 (58.2) 56.1 (59.9) 55.0 (60.3) 51.9 (52.6)
LF/HF 2.1 (1.4) 2.2 (1.5) 2.2 (1.5) 1.8 (1.1)
aAbdominal obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high fasting glucose. bn = 398.
cPatella lead × (1 – 0.0767)(difference in years between dates of bone lead and HRV measurement). dn = 400. *p for trend < 0.05. 
relation between the exposure and response to
be more flexible (Eilers and Marx 1996). This
smoothing method makes no assumptions
regarding the shape of the association (Wood
2000). The penalized splines can be estimated
in a generalized additive model using R soft-
ware (R Foundation for Statistical Computing
2006). The optimal degree of smoothing was
determined by the generalized cross-validation
criterion, which is, in practice, an approxima-
tion of Akaike’s information criterion (Wood
2000). 
Results
Table 2 shows the demographic and clinical
characteristics and HRV measurements of the
participants. All the study participants were
male, with a mean (± SD) age of 72.9 ±
6.5 years. The median tibia and patella lead
levels were 19 µg/g (IQR, 11–28 µg/g) and
23 µg/g (IQR, 15–34 µg/g), respectively. After
adjusting for the decreasing trend of patella
lead levels, the estimated median was reduced
(16.3 µg/g; IQR, 10.4–25.8 µg/g). Hereafter,
we refer to the estimated value as “patella lead.”
The correlation between tibia and patella lead
was high (Spearman correlation coefficient =
0.54). Of the subjects, 133 (32%) were identi-
fied as having MetS. BMI, waist circumfer-
ence, systolic blood pressure, fasting glucose,
total cholesterol, HDL, and triglyceride
showed statistically significant linear relations
with the number of metabolic abnormalities.
People with MetS (three or more metabolic
abnormalities) were more likely to have
ischemic heart disease and stroke and to be tak-
ing hypertension medications. In addition,
subjects with MetS showed depressed HRV
measures compared with subjects with two or
fewer metabolic abnormalities, but these differ-
ences were not statistically significant. 
Table 3 presents the prevalence of individ-
ual metabolic abnormalities and MetS and
their relationship with tertiles of age-adjusted
tibia and patella lead levels. The prevalence of
high blood pressure and hypertriglyceridemia
appeared to increase across tertiles of tibia lead
levels, whereas those trends were not observed
with patella lead levels. Instead, marginally sig-
nificant reducing trends in the prevalence of
abdominal obesity and MetS were found in
relation to patella lead levels. No statistically
significant difference was found in the preva-
lence of high fasting glucose in relation to
both tibia and patella lead levels. 
Table 4 shows the estimated change and
95% CI of various HRV parameters per one
IQR increase in each bone lead marker. After
controlling for potential confounders, we
found inverse but nonstatistically significant
associations of both tibia and patella lead levels
with HFnorm, and nonstatistically significant
positive relations with LFnorm and LF/HF.
Smoothing analysis showed that those associa-
tions were nearly linear for all HRV markers
(Figure 2). We examined whether the status of
metabolic abnormalities modified the effects
of bone lead on HRV (Table 4). For one IQR
increase in patella lead (15.4 µg/g), HFnorm
decreased by –3.9 nu (95% CI, –8.2 to
0.5 nu) and LFnorm increased by 3.9 nu (95%
CI, –0.4 to 8.3 nu) among persons with
MetS. We also observed a marginally signifi-
cant positive association between patella lead
and LF/HF among subjects with MetS
(21.2% increase; 95% CI, –1.9 to 49.8%).
However, we found no statistically significant
association in people with two or fewer meta-
bolic abnormalities. Furthermore, higher
patella lead was associated with a graded sig-
nificant reduction in HFnorm (p for trend =
0.048) and increases in LFnorm (p for trend =
0.047) and LF/HF (p for trend = 0.045) as the
number of metabolic abnormalities increased.
No statistically significant interaction was
found between metabolic abnormalities and
tibia lead in relation to HRV measures. 
We also assessed effect modifications by
individual components of MetS, such as
abdominal obesity, diabetes, hypertension,
and dyslipidemia. We only report results for
patella lead (Figure 3) because no statistically
significant interaction with tibia lead was
found. When we combined data on persons
with two or fewer metabolic abnormalities
and compared them with data on persons
with MetS, the differences in the effect of
patella lead on all HRV measures were mar-
ginal. We did find statistically significant
interactions between hypertension (use of
antihypertensive medication or blood pressure
≥ 160/96 mmHg) and patella lead for HFnorm
(p = 0.047 for interaction term) and LF/HF
(p = 0.042 for interaction term). For each
one IQR increase in patella lead, HFnorm
Low-level lead, metabolic syndrome, and HRV
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Table 3. Prevalence of individual metabolic abnormalities and MetS in the Normative Aging Study.
Abdominal Low HDL High blood pressure High fasting glucose
obesity Hypertriglyceridemia cholesterol or medication use or medication use MetS
Total (%)a 35.8 26.4 25.4 66.8 33.4 32.2
Tertile of age-adjusted tibia lead (%)
< 14.1 µg/g (n = 138) 36.2 22.5 23.2 64.5 33.3 31.2
14.1–23.8 µg/g (n = 138) 37.2 25.4 24.6 60.9 29.7 30.4
> 23.8 µg/g (n = 137) 35.0 31.4 28.5 75.2 37.2 35.0
p for trend 0.84 0.09 0.32 0.06 0.50 0.49
Tertile of age-adjusted patella leadb (%)
< 13.2 µg/g (n = 132) 40.2 28.8 31.8 65.9 31.1 37.1
13.2–22.2 µg/g (n = 133) 36.8 29.3 24.1 63.9 35.3 33.1
> 22.2 µg/g (n = 133) 29.3 21.1 23.3 66.9 34.6 27.1
p for trend 0.07 0.15 0.12 0.86 0.54 0.08
an = 413. bn = 398.
Table 4. The estimated change (95% CI) in HRV parameters associated with one IQR increase in bone lead markers. 
Tibia Patella
No. HFnorm (nu) LFnorm (nu) Log10 LF/HF (%) No. HFnorm (nu) LFnorm (nu) Log10 LF/HF (%)
All
Model 1 413 –1.1 (–4.1 to 1.9) 1.2 (–1.8 to 4.2) 4.6 (–9.8 to 21.3) 398 –0.6 (–3.1 to 1.9) 0.6 (–1.9 to 3.1) 3.0 (–8.9 to 16.5)
Model 2 413 –0.9 (–3.8 to 2.1) 0.9 (–2.0 to 3.9) 3.3 (–10.7 to 19.5) 398 –0.6 (–3.1 to 1.9) 0.6 (–1.9 to 3.1) 3.0 (–8.7 to 16.2)
No. of metabolic abnormalitiesa
0 60 –3.8 (–12.5 to 4.9) 4.0 (–4.8 to 12.7) 22.6 (–20.3 to 88.4) 60 3.7 (–3.8 to 11.2) –3.5 (–11.0 to 4.0) –16.1 (–41.7 to 20.8)
1–2 220 0.1 (–3.7 to 3.9) –0.03 (–3.9 to 3.8) –3.0 (–19.7 to 17.2) 209 0.7 (–2.6 to 4.0) –0.8 (–4.1 to 2.5) –3.4 (–17.8 to 13.4)
≥ 3 133 –2.7 (–7.9 to 2.5) 2.7 (–2.5 to 7.9) 15.6 (–10.5 to 49.4) 129 –3.9 (–8.2 to 0.5)* 3.9 (–0.4 to 8.3)* 21.2 (–1.9 to 49.8)*
p-Value for trend 0.896 0.920 0.808 0.048 0.047 0.045
IQR increase: 17 µg/g for tibia lead and 15.4 µg/g for patella lead. Model 1: adjusted for age, cigarette smoking, alcohol consumption, room temperature, and season. Model 2: further
adjusted for BMI; fasting glucose; HDL cholesterol; triglyceride; and use of β-blockers, calcium channel blockers, and/or ACE inhibitors.
aAll models adjusted as model 1. *p < 0.1.
decreased by 2.5 nu (95% CI, –5.5 to 0.55 nu)
in persons with hypertension, whereas it
increased by 2.7 nu (95% CI, –1.5 to 7.0 nu)
in persons without hypertension. Similarly,
among the same groups of subjects, one IQR
increase in patella lead was associated with a
13.0% (95% CI, –2.4 to 30.8%) change in
LF/HF among subjects with hypertension and
a –12.9% (95% CI, –29.2 to 7.0%) change in
LF/HF among those without hypertension. In
addition, higher patella lead was consistently
associated with lower HFnorm and higher
LFnorm and LF/HF among obese or diabetic
persons. However, the associations were not
significant whether persons had those condi-
tions or not, and interactions were not statisti-
cally significant. We also examined whether
obesity, ischemic heart disease, use of statin,
or use of antihypertensive medication, such as
β-blockers and calcium channel blockers,
modified the effects of bone lead on HRV,
but no statistically significant interaction was
observed (data not shown).
Discussion
Results of the present study suggest that per-
sons with multiple metabolic abnormalities are
subject to significantly stronger effects from
cumulative lead exposure, as reflected in patella
bone, on a reduction in HFnorm, a marker of
parasympathetic (vagal) nerve activity, and on
elevations in LFnorm, a marker of sympathetic
activity, and LF/HF ratio, a marker of sympa-
thovagal balance. These associations became
gradually stronger as the number of metabolic
abnormalities increased. We also observed
subjects with MetS or individual components
were consistently more affected by patella lead
than those without MetS or individual com-
ponents. Elevated LF/HF reflects sympathetic
excitation and parasympathetic withdrawal,
which may be linked with cardiac events such
as ventricular arrhythmias and myocardial
infarction (Task Force 1996). When the
cohort was not stratified by number of meta-
bolic abnormalities, trends were in the
expected direction but were not statistically
significant, presumably because of the direc-
tion of the association among people without
metabolic abnormalities being opposite to the
association among people with MetS.
The biologic mechanisms that link lead
exposure with alterations in the autonomic
nervous system are not well understood.
Redox-inactive metals such as lead deplete
glutathione and protein-bound sulfhydryl
groups, resulting in the production of ROS
such as hydroxyl radicals, because lead has a
high affinity for sulfhydryl groups (Gurer and
Ercal 2000). Many studies have confirmed
that lead exposure is associated with lipid per-
oxidation, alterations in antioxidant enzyme
activities such as superoxide dismutase and
glutathione peroxidase, and DNA damage
(Fracasso et al. 2002; Oktem et al. 2004;
Sandhir and Gill 1995; Ye et al. 1999).
Oxidative stress is known to produce pro-
inflammatory mediators, inhibit nitric oxide,
and alter calcium homeostasis, which may be
linked with sympathetic excitation and vagal
withdrawal (Ding et al. 2000; Dursun et al.
2005; Vaziri 2002). Lead modifies the intra-
cellular calcium messenger system and disturbs
calcium homeostasis because lead mimics cal-
cium and enters cells via calcium channels
(Kober and Cooper 1976; Sandhir and Gill
1994). Lead exposure down-regulates nitric
oxide production (Vaziri 2002), which causes
an increase in sympathetic and a reduction in
vagal activity (Chowdhary et al. 2002). 
Conflicting results were reported in stud-
ies of workers occupationally exposed to lead.
Studies of male workers with above-average
blood lead levels (average ~ 35 µg/dL) found
significantly diminished vagal activity as
measured by the coefficient of variation in
R–R intervals compared with nonexposed
controls at rest (Murata and Araki 1991;
Murata et al. 1993) and during deep breath-
ing (Teruya et al. 1991), whereas no associa-
tion was found among battery workers with
mean blood lead of 51 µg/dL (Gennart et al.
1992). These conflicting results may be due
to different geographical areas and age groups
studied, or because investigators did not con-
sider potential effect modification by the
underlying oxidative stress, such as metabolic
syndrome.
MetS, also known as syndrome X or
insulin resistance syndrome, is a set of cardio-
vascular risks that increases the likelihood of
developing type 2 diabetes, hypertension, and
coronary artery disease (Moller and Kaufman
2005). From analysis based on the National
Health and Nutrition Examination Survey III
data, the age-adjusted prevalence of MetS was
24% overall and 42% among those ≥ 70 years
of age (Ford et al. 2002). An estimated 47 mil-
lion U.S. residents have MetS based on 2000
census data (Ford et al. 2002). Several large
prospective studies have shown associations
between MetS and increased risks of cardio-
vascular disease as well as all-cause mortality
(Ford 2005; Malik et al. 2004). In the present
study, approximately 32% of the participants
(mean age 73 years) had MetS; this relatively
low prevalence probably reflects the predomi-
nant white population of the Normative
Aging Study cohort. 
MetS is known to be associated with low
HRV (Hemingway et al. 2005; Liao et al.
1998; Pikkujamsa et al. 1998). This is likely
because people with MetS tend to have a
greater percentage of adipose tissue (related to
insulin resistance, glucose intolerance, and
increased inflammation), atherogenic dyslipi-
demia, hypertension, and a higher proinflam-
matory and prothrombotic state, all of which
Park et al.
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Figure 2. Associations of the HRV measures HFnorm (A,B), LFnorm (C,D) and log LF/HF (E,F) with tibia lead
(A,C,E) and patella lead (B,D,F) adjusted for age, BMI, fasting glucose, HDL, triglyceride, cigarette smoking,
alcohol consumption, use of β-blockers, calcium channel blockers, and/or ACE inhibitors, room temperature,
and season. The solid line indicates the nonparametric trends estimated from the penalized spline method,
and the dotted lines indicate its 95% CIs. The optimal degree of smoothing determined by the generalized
cross-validation criterion for all HRV measures was 1, which means the associations were nearly linear.
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are associated with decreased parasympathetic
and increased sympathetic tone (Moller and
Kaufman 2005). A possible explanation of our
results is that the combined oxidative stress
and resulting overexposure to ROS caused by
long-term exposure to lead and MetS increases
the risk of autonomic dysfunction. The
observed significant interaction between
hypertension and patella lead levels in relation
to HRV may have a similar explanation:
hypertension is associated with depressed
HRV (Schroeder et al. 2003; Singh et al.
1998) and has been shown to modify the asso-
ciation between HRV and other ROS-gener-
ating factors, such as particulate matter (Park
et al. 2005). Nonstatistically significant but
consistent alterations in HRV measures only
among persons with diabetes or abdominal
obesity support the contention that proinflam-
matory conditions play a role in susceptibility
to the autonomic impact of lead exposure. 
We found that patella lead, but not tibia
lead, had interactive effects with MetS on
HRV. This differential sensitivity may be due
to different lead kinetics in the two types of
bone, cortical (tibia) bone and trabecular
(patella) bone. Because the half-life of lead is
decades in the tibia and only a few years in the
patella, tibia lead reflects long-term cumulative
lead exposure, whereas patella lead indicates
the predominant skeletal source of circulating
lead (Hu et al. 1998). Because patella lead is a
more readily mobilizable bone source of lead
than tibia lead, it may be a better marker in
the association with HRV. 
We could not evaluate the association
between blood lead and HRV because most
blood lead measurements among the Normative
Aging Study participants were not obtained at
the time of HRV measurement; thus, those
levels could not be presumed to be a marker of
lead exposure at the time of HRV measure-
ment. As discussed above, several studies have
shown an association between blood lead and
alterations in autonomic function among occu-
pationally exposed subjects with very high
blood lead levels (Bockelmann et al. 2002;
Murata and Araki 1991; Murata et al. 1993;
Teruya et al. 1991). Therefore, further studies
of the relationship between blood lead and
HRV in a general population not occupation-
ally exposed to lead are needed to determine
whether contemporary exposure to lead is an
important predictor of autonomic dysfunction. 
The present study has several limitations.
Although we collected information on many
factors that might influence autonomic nervous
system function, those factors could not
account for all the variation in HRV. However,
we tried to control for many potential con-
founding factors including age, BMI, blood
glucose, cigarette smoking, and alcohol con-
sumption. We controlled for blood lipid pro-
files (HDL and triglyceride), although these
did not change the associations we observed
because these variables account for some vari-
ance in HRV. We measured the ECG at a
stable temperature and adjusted for the tem-
perature of the room where the ECG was
taken. Additionally, we adjusted for season,
because HRV indexes of healthy men vary
physiologically by season, with lowest values in
the winter (Kristal-Boneh et al. 2000).
Therefore, the observed findings are less likely
to reflect bias due to these confounding factors.
We analyzed subjects who had bone lead
levels available (approximately 77% of all
Normative Aging Study subjects who had ECG
measurements). However, our research group
has previously found no important differences
between Normative Aging Study participants
who did and did not have bone lead levels avail-
able (Cheng et al. 1998). Therefore, we believe
that the participants of this study represent the
entire cohort. 
In addition, the Normative Aging Study
cohort is all male and almost all white. Thus,
while sex and race cannot bias our results
(both are known to be important determi-
nants of HRV), the results of this study may
not be generalizable to females or nonwhite
ethnic populations. 
This population-based study supports the
hypotheses that the autonomic effects of
cumulative lead exposure become gradually
stronger with the number of metabolic abnor-
malities and that elderly men with individual
components of MetS are more susceptible to
cardiac autonomic dysfunction (as measured
by HRV) in association with chronic lead
exposure as measured in patella. The modifi-
cation by MetS could be consistent with the
hypothesis that the oxidative stress response
is an important mechanism by which lead
toxicity affects the cardiovascular system. 
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